Omda : Q4 2023 Presentation

Q4 2023 Presentation

1 March 2024

Today's presenters

Sverre Flatby	Einar Bonnevie
Chief Executive Officer	Chief Financial Officer
18 years with Omda	15 years with Omda
9.7% equity stake in Omda1)	9.7% equity stake in Omda1)

Note: 1) Through Equilibrium AS

2

Vision:

Smarter ways to a safe and healthy world

Mission:

Providing proven, focused software for health and emergency professionals to know more and work smarter.

3

Specialised software ->long-term income predictability

Risk of customer churn

Primary

care

Community

care

Long-term

care

Omda's organic growth and M&A strategy secures long-term recurring revenues with low churn

Emergency Specialised

care care

Length of solution replacement projects

4

Software niches - business areas

Emergency		Woman & Child		Medication Management
Managing every aspect of the		Safeguarding pregnancy,		Decision support, safe and
emergency response value chain		childbirth and infancy		effective oncology treatments

Connected Imaging

LIMS

Health Analytics

Leading imaging solutions and	End-to-end blood, cell, and tissue
secure information sharing	management

Improving the quality of medical data from collection to analysis

5

Long-term recurring revenue with minimal churn….

1

Recurring Revenue

78%

4 Otherincome

2

License Sales

1 Sales

split FY 2023 4

2	3	2%	3	Professional
			Services

18%

3%

Recurring revenue

Software revenue

Semi-recurring

6

…from solid public healthcare customers

>20

years

>10

years

Note: 1) Churn of recurring revenue from lost contracts

Solid counterparties

+90% of revenue from public healthcare accounts

High stickiness

Predictable revenues for years, sometimes decades

High diversification

+600 contracts across

27 countries

• 2% churn1)

Mission-critical systems favours contract continuity

7

Performance Q4-2023 compared to Q4-2022

109 MNOK

Q4'23

vs 98 MNOK Q4'22

6,6%

COGS Q4´23

vs 10% Q4´22

11%

Income growth

Q4'23 vs Q4'22

60%

Salary cost Q4'23

vs 75% Q4'22

(% of total revenue)

12%

Annual

revenue

growth YoY

2023 vs

2022

283

Employees

Q4'23

vs 315 Q4'22

19%

EBITDA margin Q4'23

vs -21% Q4'22

15%

Other cost Q4'23

vs 22% Q4'22

(% of total revenue)

8

Performance 2H-2023 compared to 1H-2023

1H 2023

8%

EBITDA margin

2H 2023

23%

EBITDA margin

9

Decentralisation drives the margin improvement

Management team driving the overall strategy and direction including support functions

Business Area

Manager

Connected

Imaging

Business Area

Manager

Woman & Child

Business Area

Manager

Medication

Management

Business Area

Manager

LIMS

Business Area

Manager

Health

Analytics

Business Area

Manager

Emergency

Business Area

Manager

Aygo AS

	Each Business Area Manager acts as "CEO" in its business area
Organic Growth	P&L	Capital Discipline	BIB	Consulting profit centre
Incentivised to deliver on	Incentivised to deliver on	Monitoring R&D capex	Decentralised BIB processes	Development, testing and
consulting at market prices -
spend and cash conversion
organic growth	EBITDA	reduce time-to-finalisation	both internally and
per business area
			externally
				10